St Jude Medical Inc. (STJ): Today's Featured Health Care Loser

St Jude Medical ( STJ) pushed the Health Care sector lower today making it today's featured Health Care loser. The sector as a whole was unchanged today. By the end of trading, St Jude Medical fell 53 cents (-1.4%) to $38.61 on average volume. Throughout the day, three million shares of St Jude Medical exchanged hands as compared to its average daily volume of 3.5 million shares. The stock ranged in price between $38.32-$39.10 after having opened the day at $38.93 as compared to the previous trading day's close of $39.14. Other company's within the Health Care sector that declined today were: Sunshine Heart ( SSH), down 14.2%, Telik ( TELK), down 13.9%, Zogenix ( ZGNX), down 10.5%, and Ampio Pharmaceuticals ( AMPE), down 9.3%.

St. Jude Medical, Inc. develops, manufactures, and distributes cardiovascular and implantable neurostimulation medical devices worldwide. It operates in four segments: Cardiac Rhythm Management, Cardiovascular, Atrial Fibrillation, and Neuromodulation. St Jude Medical has a market cap of $12.32 billion and is part of the health services industry. The company has a P/E ratio of 15.9, equal to the average health services industry P/E ratio and below the S&P 500 P/E ratio of 17.7. Shares are up 14.5% year to date as of the close of trading on Tuesday. Currently there are 16 analysts that rate St Jude Medical a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates St Jude Medical as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front, Complete Genomics ( GNOM), up 43.6%, Hemispherx Biopharma ( HEB), up 19.7%, Amyris ( AMRS), up 18.7%, and Stereotaxis ( STXS), up 16.4%, were all gainers within the health care sector with GlaxoSmithKline ( GSK) being today's featured health care sector winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).